

Vitreous-Retina-Macula Consultants of New York

[View the current Vitreous-Retina-Macula Consultants of New York Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/31834-Vitreous-Retina-Macula+Consultants+of+New+York.html)

(<http://www.bioportfolio.com/bi corporate/31834-Vitreous-Retina-Macula+Consultants+of+New+York.html>)

Contact Details:

460 Park Avenue 5th Floor
New York
New York
10022
United States of America

Tel: 212-861-9797

Fax: (212) 628-0698

Email: mail@vrmny.com

Welcome to VRMNY.com, the web-site for Vitreous-Retina-Macula Consultants of New York, one of the premier single-specialty retina groups in the world. We are the largest retina practice in New York and one of the first to be established in the United States as a whole. The doctors of Vitreous-Retina-Macula Consultants of New York are leaders in the field who have been instrumental in the development of world-wide standards for treatment of medical and surgical retinal disease. The physicians have published literally thousands of journal articles and authored several of the major standard texts in the field. They are respected educators and frequently lecture across the country and in Europe and Asia. In this site, we describe our practice and provide important clinical information for patients and their families. As this site develops, we will be adding topics to the Patient Information section and updating the materials as new information becomes available in the field.

Recent Publications by Vitreous-Retina-Macula Consultants of New York:



- [Retinal arteriolar macroaneurysm and congenital retinal macrovessel.](#)
Variations in the morphology of the aneurysm and its serosanguineous... 24th September, 2009
Vitreous-Retina-Macula Consultants of New York, and the LuEsther T. Mertz- Ophthalmic Surg Lasers Imaging. 2009 Sep-Oct;40(5):513-5. doi: ([DOI Direct Link](#))
- [Diffuse unilateral subacute neuroretinitis masquerading as a white-dot syndrome.](#)
Variations in the morphology of the aneurysm and its serosanguineous... 28th May, 2009
Vitreous-Retina-Macula Consultants of New York, New York, NY 10022, USA.- Br J Ophthalmol. 2009 May;93(5):574-6, 655. ([DOI Direct Link](#))
- [Age-related choroidal atrophy.](#)
PURPOSE: To report the clinical characteristics of a newly defined entity,... 1st May, 2009
Vitreous-Retina-Macula Consultants of New York and the LuEsther T. Mertz- Am J Ophthalmol. 2009

- May;147(5):801-10. Epub 2009 Feb 20. ([DOI Direct Link](#))
- [A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes.](#)
*PURPOSE: To measure macular choroidal thickness in normal eyes at...*1st May, 2009
 Vitreous-Retina-Macula Consultants of New York, New York, New York 10022,- Am J Ophthalmol. 2009 May;147(5):811-5. Epub 2009 Feb 20. ([DOI Direct Link](#))
 - [Spectral domain optical coherence tomographic findings of occult macular dystrophy.](#)
*Occult macular dystrophy is a rare macular disorder in which patients have...*22nd April, 2009
 Vitreous-Retina-Macula Consultants of New York, New York, New York, USA.- Ophthalmic Surg Lasers Imaging. 2009 Mar-Apr;40(2):174-6.
 - [Spectral and time domain OCT measure identical retinal thickness if identical boundaries are selected for analysis.](#)
*Variations in the morphology of the aneurysm and its serosanguineous...*18th April, 2009
 Vitreous Retina Macula Consultants of New York, New York, NY, USA.- Eye. 2009 Apr 17. ([DOI Direct Link](#))
 - [Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration.](#)
*PURPOSE: To describe the internal structure of pigment epithelial...*17th April, 2009
 Vitreous-Retina-Macula Consultants of New York and the LuEsther T. Mertz- Am J Ophthalmol. 2009 Apr;147(4):644-52. Epub 2009 Jan 18. ([DOI Direct Link](#))
 - [Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.](#)
*PURPOSE: To evaluate intravitreal injection of ranibizumab as a potential...*14th February, 2009
 Vitreous-Retina-Macula Consultants of New York and the LuEsther T. Mertz- Am J Ophthalmol. 2009 Feb;147(2):298-306. Epub 2008 Oct 17. ([DOI Direct Link](#))
 - [Enhanced depth imaging spectral-domain optical coherence tomography.](#)
*PURPOSE: To describe a method to obtain images of the choroid using...*24th October, 2008
 Vitreous-Retina-Macula Consultants of New York, LuEsther T. Mertz Retinal- Am J Ophthalmol. 2008 Oct;146(4):496-500. Epub 2008 Jul 17. ([DOI Direct Link](#))
 - [Photoreceptor outer segment abnormalities as a cause of blind spot enlargement in acute zonal occult outer retinopathy-complex diseases.](#)
*PURPOSE: To investigate the correlation between visual field (VF) defects...*23rd July, 2008
 Vitreous-Retina-Macula Consultants of New York and the LuEsther T. Mertz- Am J Ophthalmol. 2008 Jul;146(1):111-20. Epub 2008 Apr 24. ([DOI Direct Link](#))
 - [Ultrastructural correlation of spectral-domain optical coherence tomographic findings in vitreomacular traction syndrome.](#)
*PURPOSE: To examine the ultrastructural correlates of spectral-domain...*23rd July, 2008
 Vitreous-Retina-Macula Consultants of New York, and the LuEsther T. Mertz- Am J Ophthalmol. 2008 Jul;146(1):121-7. Epub 2008 Apr 25. ([DOI Direct Link](#))
 - [Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.](#)
*PURPOSE: To determine the incidence of endophthalmitis following...*21st May, 2008
 Vitreous Retina Macula Consultants of New York, NY, USA.- Am J Ophthalmol. 2008 May;145(5):879-82. Epub 2008 Mar 10. ([DOI Direct Link](#))
 - [Fundus autofluorescence in multifocal choroiditis and panuveitis.](#)
*PURPOSE: To investigate the autofluorescence findings associated with...*21st May, 2008
 Vitreous Retina Macula Consultants of New York, New York, New York, USA.- Am J Ophthalmol. 2008 May;145(5):847-53. Epub 2008 Mar 10. ([DOI Direct Link](#))
 - [Fundus autofluorescence in birdshot chorioretinopathy.](#)
*PURPOSE: To investigate the characteristics of fundus autofluorescence in...*7th May, 2008
 Vitreous-Retina-Macula Consultants of New York, New York, New York 10022,- Ophthalmology. 2008 May;115(5):e15-20. Epub 2008 Apr 18. ([DOI Direct Link](#))
 - [Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral-domain optical coherence tomography.](#)

PURPOSE: To delineate the 3-dimensional (3-D) relationship in...2nd April, 2008
 Vitreous-Retina-Macula Consultants of New York, Manhattan Eye, Ear, and- Am J Ophthalmol. 2008
 Mar;145(3):509-517. Epub 2008 Jan 11. ([DOI Direct Link](#))

Press Releases on Vitreous-Retina-Macula Consultants of New York:

Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill	7th November, 2009	United States Conference of Catholic Bishops	WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ -- The U.S. bishops November 7 urged members of the House of Representatives to vote for the Stupak-Ellsworth Amendment to the health care reform. "The
Hospira to Present at Piper Jaffray 21st Annual Health Care Conference Dec. 2	6th November, 2009	Hospira, Inc.	LAKE FOREST, Ill., Nov. 6 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that the company will present
Centene Corporation to Present at Upcoming Healthcare Conferences	6th November, 2009	Centene Corporation	ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at two upcoming healthcare conferences over the next few weeks. Next week, at the
Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering	6th November, 2009	Trius Therapeutics, Inc.	SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a
DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009	6th November, 2009	DUSA Pharmaceuticals, Inc.	WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

